5CV — CureVac NV Share Price
0.000.00%
Last trade - 00:00- €602.83m
- €435.62m
- €53.76m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.6 | ||
| Price to Tang. Book | 1.72 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 9.15 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -64.67% | ||
| Return on Equity | -54.3% | ||
| Operating Margin | -438.8% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 17.42 | 48.87 | 102.99 | 67.42 | 53.76 | 108.36 | 59.81 | 33.1% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CureVac AG is a clinical-stage biopharmaceutical company, The Company strives to create transformative medicines to protect and improve people’s lives. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.
Directors
- Baron Stephenne CSU (71)
- Franz-Werner Haas CEO (52)
- Friedrich von Bohlen und Halbach VSU (59)
- Pierre Kemula CFO (47)
- Mariola Fotin-Mleczek CTO (54)
- Igor Splawski CSO (53)
- Antony Blac MGB (53)
- Senta Gnad-Vogt MGB (49)
- Florian Von der Mulbe MGB (48)
- Hans Tanner IND (71)
- Craig Tooman IND (55)
- Viola Bronsema SUB (58)
- Ralf Clemens SUB (68)
- Mathias Hothum SUB (54)
- Timothy Wright SUB (65)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- April 7th, 2020
- Public Since
- August 14th, 2020
- No. of Employees
- 999
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- XETRA
- Shares in Issue
- 224,314,013
- Address
- Friedrich-Miescher-Str. 15, TUEBINGEN, 72076
- Web
- https://www.curevac.com/
- Phone
- +49 707198830
- Contact
- Sarah Fakih
- Auditors
- KPMG AG Wirtschaftsprufungsgesellschaft
Upcoming Events for 5CV
Similar to 5CV
FAQ
What is the CureVac NV share price?
As of Today at 20:09 UTC, shares in CureVac NV are trading at €2.72. This share price information is delayed by 15 minutes.
How has the CureVac NV share price performed this year?
Shares in CureVac NV last closed at €2.72 and the price had moved by -52.29% over the past 365 days. In terms of relative price strength the CureVac NV share price has underperformed the FTSE Global All Cap Index by -59.08% over the past year.
What are the analyst and broker recommendations for CureVac NV?
The overall consensus recommendation for CureVac NV is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the CureVac NV dividend yield?
CureVac NV does not currently pay a dividend.
Does CureVac NV pay a dividend?
CureVac NV does not currently pay a dividend.
When does CureVac NV next pay dividends?
CureVac NV does not currently pay a dividend.
How do I buy CureVac NV shares?
To buy shares in CureVac NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of CureVac NV?
As of the previous close price of €2.72, shares in CureVac NV had a market capitalisation of €602.83m.
Where are CureVac NV shares listed?
Here are the trading details for CureVac NV:
- Country of listing: Germany
- Exchange: GER
- Ticker Symbol: 5CV
What kind of share is CureVac NV?
Based on an overall assessment of its quality, value and momentum CureVac NV is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a CureVac NV share price forecast for 2024?
The analyst consensus target price for shares in CureVac NV is €7.18. That is 163.56% above the last closing price of €2.72.
Analysts covering CureVac NV currently have a consensus Earnings Per Share (EPS) forecast of -€0.37 for the next financial year.
Find out moreWhat is the trend in the CureVac NV share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CureVac NV. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -7.42%.
As of the last closing price of €2.72, shares in CureVac NV were trading -13.47% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the CureVac NV PE Ratio?
The CureVac NV PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €2.72.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of CureVac NV?
CureVac NV's management team is headed by:
- Baron Stephenne - CSU
- Franz-Werner Haas - CEO
- Friedrich von Bohlen und Halbach - VSU
- Pierre Kemula - CFO
- Mariola Fotin-Mleczek - CTO
- Igor Splawski - CSO
- Antony Blac - MGB
- Senta Gnad-Vogt - MGB
- Florian Von der Mulbe - MGB
- Hans Tanner - IND
- Craig Tooman - IND
- Viola Bronsema - SUB
- Ralf Clemens - SUB
- Mathias Hothum - SUB
- Timothy Wright - SUB